<DOC>
	<DOCNO>NCT02170844</DOCNO>
	<brief_summary>To investigate compare safety , pharmacokinetics pharmacodynamics BIBR 1048 MS follow oral administration single rise dos 50 mg 350 mg healthy male subject Japanese Caucasian origin . This first administration substance subject Japanese origin .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics After Single Rising Oral Doses BIBR 1048 MS Capsules Healthy Subjects Japanese Caucasian Origin</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR , Respiratory Rate tympanic body temperature ) , 12 lead ECG , clinical laboratory test 1.1 . No find deviate normal clinical relevance 1.2 . No evidence clinically relevant concomitant disease 2 . Age ≥20 Age ≤45 year 3 . BMI ≥18 BMI ≤25 kg/m2 ( Body Mass Index ) 4 . Japanese subject welldefined Japanese population , parent Japanese origin subject Japanese passport live ≤ 8 year outside Japan . 5 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . 1 . Current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . An unwillingness male subject abstain sexual intercourse pregnant lactate woman , unwillingness male subject use adequate form contraception well female partner ( ) use another form contraception ( woman could become pregnant ) time first dose administration follow 3 . Current diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder 4 . History clinically significant orthostatic hypotension , clinically significant current past fainting spell blackout . 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator bleed disorder include prolonged habitual bleeding hematologic disease cerebral bleeding ( e.g . car accident ) concussion ( head trauma result injure brain ) without loss consciousness 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives , whichever short , respective drug prior administration trial 8 . Use AcetylsalicylicAcid ( ASA ) contain overthecounter medication , clopidogrel ticlopidine dipyridamole , chronic administration Non Steroidal Antiinflammatory Drugs ( NSAIDs ) ( COX2 inhibitor exclude ) , coumadin like anticoagulant , chronic use corticosteroid , heparin fibrinolytic agent within 14 day prior administration trial . 9 . Use medication include counter ( medicinal cream , vitamin , eye drop etc . ) within 7 day prior administration trial . 10 . Participation another trial investigational drug within three month prior administration trial 11 . Smoker ( &gt; 10 cigarettes/day &gt; 3 cigars/day &gt; 3 pipes/day ) 12 . Inability refrain smoke trial day 13 . Alcohol abuse ( 21unit/week ) 14 . History drug abuse 15 . Blood donation ( 100 mL within three month prior screen administration blood donation screen followup ) 16 . Excessive physical activity ( within one week prior administration trial followup ) 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen study centre 19 . Known hypersensitivity drug excipients Exclusion criterion specific study : 20 . History familial bleeding disorder 21 . Thrombocytes &lt; 150000/micro L</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>